701 related articles for article (PubMed ID: 28193518)
1. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
[TBL] [Abstract][Full Text] [Related]
6. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
7. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
[TBL] [Abstract][Full Text] [Related]
8. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Zeuzem S; Ghalib R; Reddy KR; Pockros PJ; Ben Ari Z; Zhao Y; Brown DD; Wan S; DiNubile MJ; Nguyen BY; Robertson MN; Wahl J; Barr E; Butterton JR
Ann Intern Med; 2015 Jul; 163(1):1-13. PubMed ID: 25909356
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
[TBL] [Abstract][Full Text] [Related]
10. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
Can J Gastroenterol Hepatol; 2017; 2017():8186275. PubMed ID: 28164081
[No Abstract] [Full Text] [Related]
11. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
[TBL] [Abstract][Full Text] [Related]
12. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
[TBL] [Abstract][Full Text] [Related]
15. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
[TBL] [Abstract][Full Text] [Related]
17. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Buti M; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Forns X
Clin Infect Dis; 2016 Jan; 62(1):32-6. PubMed ID: 26371152
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
Huang CF; Hung CH; Cheng PN; Bair MJ; Huang YH; Kao JH; Hsu SJ; Lee PL; Chen JJ; Chien RN; Peng CY; Lin CY; Hsieh TY; Cheng CH; Dai CY; Huang JF; Chuang WL; Yu ML
J Infect Dis; 2019 Jul; 220(4):557-566. PubMed ID: 30957170
[TBL] [Abstract][Full Text] [Related]
19. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
